Articles

In a retrospective study of 45 breast cancer patients, the differential expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 is evaluated in primary and relapsed tumors. The conversion rate of these biomarkers and their prognostic relevance are assessed. Read More ›

Eribulin mesylate is an inhibitor of microtubule dynamics that may play a role in reducing the abnormality of the tumor microenvironment (ie, increasing oxygenation). As hypoxic conditions may contribute to drug resistance, it is hypothesized that eribulin may enhance the efficacy of other therapies. In this study, the effects of eribulin on 2 endocrine therapies were evaluated. Read More ›

Progression-free survival (PFS) is often used as a surrogate for overall survival (OS) due to the challenges of measuring OS in relatively short-term trials, and is a practice that has been supported by previous analyses of breast cancer data. This analysis further examines the relationship between PFS and OS in advanced breast cancer. Read More ›

Tyrosine kinase inhibitors (TKIs) have dramatically improved survival in chronic myeloid leukemia (CML). Most patients achieve deep molecular responses, such that TKIs can be safely and successfully stopped. However, specific preconditions for stopping TKI treatment in CML have not been defined.

Read More ›

Nikhil Munshi talks about modifying treatment to patients' expectations and what they can tolerate. Read More ›

Nikhil Munshi would like to see more emphasis put into studies to provide reasonable costs for treatment so as to relieve the financial burden of some patients. Read More ›

Nikhil Munshi believes caregivers should be informed about the newer medicines so they can be aware of potential side effects as well as medicine's responsibility to take a holistic approach to patients' lives post-treatment. Read More ›

Joseph Connors, MD, explains how the understanding of the disease has evolved leading to the categorization of subsets and consequently resulted in the development of newer therapies to address these subsets. Read More ›

Leaders in hematology will present data from 6 research efforts that have been recognized as top abstracts in this year’s Congress. Leukemias – acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) –feature prominently. Read More ›

This poster session spotlights clinical trial data for commercialized and emerging therapies with activity in adults and children with acute lymphoblastic leukemia (ALL). Novel therapies include inotuzumab ozogamicin, ponatinib, and bortezomib. Read More ›